See more : L.P.N. Development Public Company Limited (LPN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Odyssey Group International, Inc. (ODYY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odyssey Group International, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- CSI Properties Limited (0497.HK) Income Statement Analysis – Financial Results
- Sonel S.A. (SON.WA) Income Statement Analysis – Financial Results
- AI,Inc. (4388.T) Income Statement Analysis – Financial Results
- Net Insurance S.p.A. (NET.MI) Income Statement Analysis – Financial Results
- Zhejiang Zheneng Electric Power Co., Ltd. (600023.SS) Income Statement Analysis – Financial Results
Odyssey Group International, Inc. (ODYY)
About Odyssey Group International, Inc.
Odyssey Health, Inc., a medical company, focuses on developing medical products. It develops CardioMap, a heart monitoring and screening device; Save A Life choking rescue devices; and PRV-001 and PRV-002 neurosteroid drug compounds to treat concussions and rare brain disorders. The company was formerly known as Odyssey Group International, Inc. Odyssey Health, Inc. was founded in 2014 and is based in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 266.17K | 0.00 | 0.00 | 0.00 | 37.45K | 257.22K | 0.00 |
| Cost of Revenue | 0.00 | 3.42K | 2.37K | 5.55K | 10.52K | 10.55K | 10.55K | 10.55K | 20.30K | 228.49K | 0.00 |
| Gross Profit | 0.00 | -3.42K | -2.37K | -5.55K | 255.64K | -10.55K | -10.55K | -10.55K | 17.15K | 28.73K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 96.05% | 0.00% | 0.00% | 0.00% | 45.80% | 11.17% | 0.00% |
| Research & Development | 55.17K | 201.33K | 1.32M | 9.44M | 20.24K | 23.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.51M | 2.12M | 6.79M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 90.72K | 184.63K | 406.56K |
| Selling & Marketing | 0.00 | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.51M | 4.94M | 6.79M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 90.72K | 184.63K | 406.56K |
| Other Expenses | 0.00 | 8.68K | 498.74K | 0.00 | 0.00 | 23.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -14.26M | 5.14M | 8.11M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 90.72K | 184.63K | 406.56K |
| Cost & Expenses | -14.26M | 5.14M | 8.11M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 111.02K | 413.12K | 406.56K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.75K |
| Interest Expense | 518.48K | 614.08K | 836.29K | 1.07M | 502.19K | 70.28K | 62.67K | 30.27K | 12.55K | 4.80K | 0.00 |
| Depreciation & Amortization | 1.54K | 3.42K | 2.37K | 5.55K | 10.52K | 10.55K | 10.55K | 10.55K | 5.14K | 155.90K | 406.56K |
| EBITDA | -2.14M | -5.30M | -7.61M | -6.42M | -3.84M | -23.35M | -409.89K | -157.02K | -68.43K | -155.90K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,441.25% | 0.00% | 0.00% | 0.00% | -182.71% | -60.61% | 0.00% |
| Operating Income | 14.26M | -5.31M | -8.11M | -15.86M | -3.85M | -378.14K | -420.44K | -167.58K | -73.57K | -155.90K | -406.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,445.21% | 0.00% | 0.00% | 0.00% | -196.43% | -60.61% | 0.00% |
| Total Other Income/Expenses | -15.17M | -605.41K | -337.55K | -1.02M | -502.19K | 149.72K | -62.67K | -30.27K | -12.55K | -4.80K | -28.75K |
| Income Before Tax | -905.77K | -5.92M | -8.44M | -16.88M | -4.35M | -448.43K | -483.12K | -197.84K | -86.12K | -160.70K | -435.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,633.89% | 0.00% | 0.00% | 0.00% | -229.94% | -62.47% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 337.55K | 1.07M | 502.19K | 70.28K | 131.45K | 30.27K | 12.55K | -155.90K | -28.75K |
| Net Income | -905.77K | -5.92M | -8.78M | -17.96M | -4.85M | -518.71K | -483.12K | -197.84K | -86.12K | -160.70K | -435.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,822.56% | 0.00% | 0.00% | 0.00% | -229.94% | -62.47% | 0.00% |
| EPS | -0.01 | -0.07 | -0.10 | -0.19 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.07 | -0.10 | -0.19 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 97.06M | 82.68M | 89.00M | 93.73M | 87.12M | 69.90M | 117.13M | 114.79M | 114.75M | 114.75M | 106.50M |
| Weighted Avg Shares Out (Dil) | 97.06M | 82.68M | 89.00M | 93.73M | 87.12M | 69.90M | 117.13M | 114.79M | 114.75M | 114.75M | 106.50M |
Odyssey Group International Completes IND-enabling Studies, Submits Investigator's Brochure for Phase 1 Clinical Trial
IRVINE, CA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the successful completion of their Investigational...
Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders
IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it...
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion
Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle...
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Enters Agreement with Contract Research Organization for Phase 1 Trial Enters Agreement with Contract Research Organization for Phase 1 Trial
Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders
IRVINE, CA, May 24, 2021 (GLOBE NEWSWIRE) -- – Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it...
Odyssey Group International Welcomes Global Operations and Quality Leader Ricky Richardson to Board of Directors
IRVINE, CA, May 13, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"),a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to welcome Ricky Richardson to the Company's...
Odyssey Group International Announces Formation of Scientific Advisory Board
Irvine, CA, April 14, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the formation of a Scientific Advisory...
Odyssey Group International Announces Upcoming Television Appearance by Brett Favre and Dr. Jake VanLandingham on NewsNation Now's “The Donlon Report”
IRVINE, CA / ACCESSWIRE / March 10, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Dr. Jake VanLandingham, Odyssey's...
Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug
Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021 IRVINE, CA / ACCESSWIRE / March 2, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique,...
Source: https://incomestatements.info
Category: Stock Reports